Cyclopharm Raises A$14m and Launches A$2m SPP to Accelerate US Technegas Rollout

Cyclopharm Limited ( (AU:CYC) ) has shared an announcement.

Cyclopharm Limited has raised A$14 million via a placement to new and existing institutional, sophisticated and professional investors at A$0.95 per share, issuing 14,736,842 new shares in two tranches under its existing placement capacity. The company will also launch a non-underwritten share purchase plan to raise up to a further A$2 million at the same issue price, giving eligible shareholders in Australia, New Zealand and the UK the opportunity to subscribe for up to A$30,000 in new shares. Proceeds will be directed primarily to accelerating the commercial rollout of its Technegas® lung imaging technology in the US, as well as funding Advance Beyond PE growth initiatives, development of a next-generation Technegas® system and general working capital, underscoring Cyclopharm’s push to solidify its US market entry and support its longer-term growth trajectory.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an Australian radiopharmaceutical and medical technology company best known for its Technegas® system, a diagnostic imaging agent used primarily in nuclear medicine for lung imaging. The company focuses on expanding the commercial footprint of Technegas® in international markets, with a particular strategic emphasis on growth in the United States, alongside developing next-generation systems and broader diagnostic applications.

Average Trading Volume: 65,528

Technical Sentiment Signal: Hold

Current Market Cap: A$130M

Find detailed analytics on CYC stock on TipRanks’ Stock Analysis page.